摘要
目的:以S-SEDDS替代液态自乳化制剂中的表面活性剂制备非诺贝特固体自乳化制剂。方法:比较了固体自乳化制剂与市售产品、液体自乳化制剂的体外溶出情况及体内生物利用度。结果:表明本研究的固体自乳化制剂用水分散后平均粒径为820.2±26.5(nm);溶出度试验结果显示,30min累积溶出度达到80%以上,本研究制备的非诺贝特固体自乳化制剂AUC(0-24)为22.7±8.2 mgoL-1oh与SEDDS的AUC(0-24)(24.9±7.6mgoL-1oh)没有显著性差异(P>0.05),与市售微粉化胶囊(13.8±10.5mgoL-1oh)相比能够显著提高药物的生物利用度(P<0.05)。结论:S-SEDDS有液体自乳化给药系统的效果。
Objective:The solid self-emulsified drug delivery system(S-SEDDS) of fenofibrate was investigated,which contained solid excipient instead of surfactants usually used in liquid self-emulsified drug delivery system.Methods:Particle size distribution,disso-lution rate in vitro was detected.Rerults:The average size of S-SEDDS after dispersion was 820.2 ± 26.5(nm).Dissolution test showed that the accumulated dissolution of S-SEDDS was about 80% within 30min.In vivo study,AUC(0-24) was 22.7 ±8.2 mgoL-1oh in S-SEDDS and 24.9 ± 7.6 mgoL-1oh in SEDDS.There was no significant difference between S-SEDDS and SEDDS,while they were all better than that of the market capsule(13.8±10.5 mgoL-1oh).Conclusions:S-SEDDS could enhance the dissolution rate and the bioavail-ability of fenofibrate free of surfactant.
出处
《现代生物医学进展》
CAS
2011年第7期1266-1269,共4页
Progress in Modern Biomedicine